1. Home
  2. IOVA vs TSLX Comparison

IOVA vs TSLX Comparison

Compare IOVA & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

HOLD

Current Price

$7.03

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Logo Sixth Street Specialty Lending Inc.

TSLX

Sixth Street Specialty Lending Inc.

HOLD

Current Price

$18.54

Market Cap

1.6B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IOVA
TSLX
Founded
2007
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.6B
IPO Year
2008
2011

Fundamental Metrics

Financial Performance
Metric
IOVA
TSLX
Price
$7.03
$18.54
Analyst Decision
Buy
Buy
Analyst Count
10
9
Target Price
$9.00
$21.61
AVG Volume (30 Days)
17.2M
495.7K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
10.82%
EPS Growth
14.84
N/A
EPS
N/A
0.15
Revenue
N/A
N/A
Revenue This Year
$47.74
N/A
Revenue Next Year
$40.31
$1.20
P/E Ratio
N/A
$122.93
Revenue Growth
N/A
N/A
52 Week Low
$1.76
$16.04
52 Week High
$7.25
$24.79

Technical Indicators

Market Signals
Indicator
IOVA
TSLX
Relative Strength Index (RSI) 71.00 58.89
Support Level $3.57 $18.50
Resistance Level N/A $19.75
Average True Range (ATR) 0.47 0.44
MACD 0.17 0.04
Stochastic Oscillator 89.70 72.77

Price Performance

Historical Comparison
IOVA
TSLX

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About TSLX Sixth Street Specialty Lending Inc.

Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.

Share on Social Networks: